Arcutis climbs on positive trial results for skin disease treatment

Arcutis Biotherapeutics

28/08/2024 15:35

** Shares of drugmaker Arcutis Biotherapeutics  ARQT.O  rise
~3.5% to $10.87
    ** Company says its roflumilast cream 0.05% showed durable
efficacy and favorable safety profile in a late-stage trial for
the treatment of mild to moderate atopic dermatitis (AD) in
children aged 2 to 5
    ** AD causes dry, itchy and inflamed skin 
    ** A higher dose version of the cream, roflumilast cream
0.15% or Zoryve, is approved by the U.S. FDA for the treatment
of AD in patients 6 years of age and older
    ** ARQT plans to submit a supplemental marketing application
for roflumilast cream 0.05% in Q1 2025
    ** Stock has more than tripled YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))